The Israeli government estimated this year's NIS19.18 billion ($4.53billion) budget for financing the basket of services provided under the National Health Insurance Law according to 1999's health price index.
While the 2001 budget includes a 1% (NIS186 million) rise for the financing of new drugs and technologies, and 2% more for general services, it ignores a Knesset (parliament) investigatory committee which, in 1999, recommended that the procedure for updating the NHIL services basket should take account of demographics, technological advances and health price inflation, says the Marketletter's local correspondent.
The lack of an updating mechanism has created deficits for the sick funds, which have sought in the High Court a requirement that the government should adopt a formula which reflects real costs. In an interim judgement, the Court instructed the Ministers of Health and Finance to try to reach agreement on the issue but, reportedly, they have yet to discuss it.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze